FDA Warns Against Plavix/Prilosec Negative Interaction

  • By
  • In Industry News
  • November 30, 2009
  • Comments Off on FDA Warns Against Plavix/Prilosec Negative Interaction

The U.S. Food and Drug Administration (FDA) issued a notice to health care professionals Nov. 17 of new safety information concerning an interaction between clopidogrel (Plavix), an anti-clotting medication, and omeprazole (Prilosec/Prilosec OTC), a proton pump inhibitor (PPI) used to reduce stomach acid.

New data show that when Plavix and Prilosec are taken together, the effectiveness of Plavix is reduced. Patients at risk for heart attacks or strokes who use Plavix to prevent blood clots will not get the full effect of this medicine if they are also taking Prilosec. Separating the dose of both medications in time will not reduce this drug interaction, according to the FDA.

Other drugs that are expected to have a similar effect and should be avoided in combination with Plavix include: cimetidine, fluconazole, ketoconazole, voriconazole, etraverine, felbamate, fluoxetine, fluvoxamine, and ticlopidine.

Recommendations for health care professionals are provided in the “Information for Healthcare Professionals” sheet.

Latest posts by admin aapc (see all)

Comments are closed.

Have you used AAPC's member discount savings program (e.g., travel, entertainment)? (On top menu: Resources/Other Resources/Savings Center)